Correlation Between Acrivon Therapeutics, and Aerovate Therapeutics

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Aerovate Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Aerovate Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Aerovate Therapeutics, you can compare the effects of market volatilities on Acrivon Therapeutics, and Aerovate Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Aerovate Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Aerovate Therapeutics.

Diversification Opportunities for Acrivon Therapeutics, and Aerovate Therapeutics

-0.23

Correlation Coefficient

Acrivon Therapeutics,  Aerovate Therapeutics

Very good diversification

The 3 months correlation between Acrivon and Aerovate is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Aerovate Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aerovate Therapeutics and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Aerovate Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aerovate Therapeutics has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Aerovate Therapeutics go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Aerovate Therapeutics

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the Aerovate Therapeutics. In addition to that, Acrivon Therapeutics, is 1.09 times more volatile than Aerovate Therapeutics. It trades about -0.02 of its total potential returns per unit of risk. Aerovate Therapeutics is currently generating about 0.17 per unit of volatility. If you would invest  186.00  in Aerovate Therapeutics on September 2, 2024 and sell it today you would earn a total of  77.00  from holding Aerovate Therapeutics or generate 41.4% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Aerovate Therapeutics

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Acrivon Therapeutics, is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Aerovate Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Acrivon Therapeutics, and Aerovate Therapeutics

The main advantage of trading using opposite Acrivon Therapeutics, and Aerovate Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Aerovate Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aerovate Therapeutics will offset losses from the drop in Aerovate Therapeutics' long position.

The idea behind Acrivon Therapeutics, Common and Aerovate Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.